allogeneic anti-CD19 CAR T cells ATA3219

{
  "id": "MLC-T-ONC-009802",
  "term": "allogeneic anti-CD19 CAR T cells ATA3219",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of allogeneic human Epstein-Barr virus (EBV)-sensitized T lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with a modified CD3zeta signaling domain 1xx, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD19 CAR T cells ATA3219 recognize and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The use of allogeneic EBV T cells minimizes the risks for graft-versus-host disease (GvHD). The modified CD3zeta signaling domain 1xx retains signaling capacity in 1 of 3 immune-receptor-tyrosine-based-activation-motif (ITAM) regions, which may help prevent counterproductive T-cell differentiation and exhaustion, and may enhance the anti-tumor activity of the CAR T-cells.",
  "synonyms": [
    "allogeneic anti-CD19 CAR-T cells ATA3219"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/allogeneic-anti-cd19-car-t-cells-ata3219/"
}